Phase III randomized trial of volasertib combined with low-dose cytarabine (LDAC) versus placebo plus LDAC in patients aged ≥65 years with previously untreated, acute myeloid leukemia (AML) ineligible for intensive remission induction therapy
Title:
Phase III randomized trial of volasertib combined with low-dose cytarabine (LDAC) versus placebo plus LDAC in patients aged ≥65 years with previously untreated, acute myeloid leukemia (AML) ineligible for intensive remission induction therapy
Author:
DeAngelo, Daniel J. Sekeres, Mikkael A. Ottmann, Oliver G. Sanz, Miguel A. Naoe, Tomoki Taube, Tillmann Belsack, Valerie Ge, Miaomiao Döhner, Hartmut